The next unicorn for investors on CSE, undoubtedly, is psychedelic stocks. Early day investors who invested in cannabis stocks earned big bucks because they were the firsts. We should use the same example and fund biopharmaceutical companies that facilitate psychedelic drugs to treat brain health disorders. Having entered the CSE and being listed as a publicly trading company,Bright Minds is set to build investor relationships via their psychedelic company stocks in Canada.

By launching their lead product as their main psychedelic stock, the biotechnology company starts a new wave of innovation at improving the effects of drugs such as Psilocybin.

Investors fund research and studies carried out by biotechnology companies such as Bright Minds Biosciences for their psychedelic stocks. You can now easily trade-in Bright Minds psychedelic company stock in Canada on CSE.

Important Stats For Investors About Psychedelic Stocks on CSE

1. 2200%+ Growth Rate In 2020

Following past statistics on psychedelic stocks, the early psychedelic company stocks in Canada rose by 2200%+. Investors who were the first ones bagged a gold mine by funding such stocks on CSE.

2. PRNewswire Estimates Market For Psychedelic Drugs Reaching Above $6000 Million by 2027

As per a report published on PRNewswire on June 3rd, 2020, Data Bridge Market Research forecasts the psychedelic company stocks to grow by more than 16% by 2027. In dollar amounts, it is estimated to grow from $2077 million in 2020 to above $6000 million by 2027.

3. More Countries Are Choosing To Implement Psychotherapy via Psychedelics

Since psychedelic therapies in some parts of the world, more research has emerged stating the potential effects of these psychoactive drugs on brain receptors. Some FDA-approved psychoactive drugs are already being used worldwide, such as MDMA used in Brazil for PTSD treatment.

According to a study published in the Journal of Psychopharmacology, out of the patients who administered a single dose of Psilocybin to treat depression and anxiety, almost 80% of them continued psychedelic therapy sessions. Changes observed in them were the improved quality of life, lower distress levels, and improved health.

Such studies increased significantly in 2020, and more countries plan to implement the potential use of these naturally occurring drugs.

More market for demand of these psychoactive substances leads to more supply of the same. Hence, investors can greatly benefit by investing in psychedelic stocks by Bright Minds Biosciences Inc. (DRUG).

4. More Than 200 Million People Globally Suffer From Mental Health Disorders

The approximate number is around 264 million. It is a statistic released by WHO, and while it is an alarming number, it can be reduced by the commercialization of psychedelic drugs.

After the Canadian government lifted the ban on Psilocybin, a psychoactive compound in magic mushrooms, research scientists and drug designer have found the possibility of modifying molecules of these compounds that works to its full potential in the cure of neurological illnesses.

Bright Minds Bio has two patented serotonergic agonists in Phase 2 clinical trials at NIH (National Institute of Health). By investing in Bright Minds psychedelic stocks, investors get to see regular higher-highs on their trading charts.

Contact Info:

Website: Brightmindsbio.com
Location: Toronto, Canada